CD274 and neoplasm: In NSCLC, wild-type P53-induced miR-34 directly binds to the 3′-UTR of PD-L1 to inhibit PD-L1 mRNA expression, the therapeutic delivery of miR-34a combined with radiotherapy can increase T cell infiltration and inhibit tumor growth [243].